Back to results
US 5,854,048 AGranted
Method for treating thromboembolic conditions using thrombolytically active proteins
AssigneeBoehringer Mannheim GmbH
InventorsUlrich Martin, Stephan Fischer
Life of this patent
Estimating the term…
Abstract
The use of various thrombolytically active proteins in therapy is disclosed. The proteins are markedly superior to wild type t-PA in their pharmacokinetic, pharmacodynamic, and safety profiles.
Claims10
Process for production of a thrombolytically active protein which consists of amino acid sequence:
- ______________________________________ 1 SYQGNSDCYF GNGSAYRGTH SLTHSGASCL PWNSMILIGK VYTAQNPSAQ 51 ALGLGKHNYC RNPDGDAKPW CHVLKNRRLT WEYCDVPSCS TQGLRQYSQP 101 QFRIKGGLFA DIASHPWQAA IFAKHRRSPG ERFLCGGILI SSCWILSAAH 151 CFQERFPPHH LTVILGRTYR VVPGEEEQKF EVEKYIVHKE FDDDTYDNDI 201 ALLQLKSDSS RCAQESSVVR TVCLPPADLQ LPDWTECELS GYGKHEALSP 251 FYSERLKFAH VRLYPSSRCT SQHLLNRYVT DNMLCAGDTR SGGPQANLHD 301 ACQGDSGGPL VCLNDGRMTL VGHSWGLGC GQKDVPGVYT XVTNYLDWIR 351 DNMRP ______________________________________
- comprising transforming a host cell with a plasmid which comprises a nucleic acid molecule which encodes said thrombolytically active protein, culturing said host cell to produce said thrombolytically active protein, and isolating said thrombolytically active protein following its production.
Process for producing a thrombolytically active protein which consists of amino acid sequence:
- ______________________________________ 1 SYQGNSDCYF GNGSAYRGTH SLTESGASCL PWNSMILIGK VYTAQNPSAQ 51 ALGLGKHNYC RNPDGDAKPW CHVLKNRRLT WEYCDVPSCS TCGLRQYSQP 101 QFRIKGGLFA DIASHPWQAA IFAKHRRSPG ERFLCGGILI SSCWILSAAH 151 CFQERFPPHH LTVILGRTYR VVPGEEEQKF EVEKYIVHKE FDDDTYDNDI 201 ALLQLKSDSS RCAQESSVVR TVCLPPADLQ LPDWTECELS GYGKHEALSP 251 FYSERLKEAH VRLYPSSRCT SQHLLNRTVT DNMLCAGDTR SGGPQANLHD 301 ACQGDSGGPL VCLNDGRMTL VGHSWGLGC GQKDVPGVTT KVTNYLDWIR 351 DNMRP ______________________________________
- comprising culturing a host cell which produces said thrombolytically active protein in the form of inclusion bodies to produce said inclusion bodies, separating said inclusion bodies from said host cell, solubilizing said inclusion bodies with guanidine hydrochloride, contacting solubilized inclusion bodies with oxidized glutathione, and renaturing protein with L-arginine and GSH.
Dependencies are inferred from the claim text.